Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?

NCT ID NCT07766421

Not yet recruiting Disease control Sponsor: Cellectar Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 3 trial is testing whether a radioactive drug called iopofosine I 131 can keep Waldenstrom macroglobulinemia (a rare blood cancer) from getting worse for longer than the standard combination of rituximab, cyclophosphamide, and dexamethasone (R-CD). The study enrolls about 219 adults who have already been treated with a BTK inhibitor and now need further therapy. Participants are randomly assigned to receive either iopofosine I 131 (given by infusion over two cycles) or R-CD (up to six cycles), and the main goal is to compare how long people live without their disease progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iopofosine I 131 (also called CLR 131), a radioactive drug given by infusion
What this could lead to
If iopofosine I 131 works better than the standard combination, it could offer a new, more effective treatment option for people with Waldenstrom macroglobulinemia who have already tried a BTK inhibitor.
What could go wrong
This is a phase 3 trial, but results are not guaranteed. The drug may not prove superior, and it carries risks like radiation exposure and side effects. The trial is still recruiting and has not yet reported outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINAEMIA WALDENSTROM MACROGLOBULINEMIA WALDENSTROM MACROGLOBULINEMIA WITH NODAL DISEASE WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA RECURRENT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.